13
January
2020
|
16:10
Europe/Amsterdam

Locally developed fatty liver medicines possibly launched earlier with acquisition of related intellectual property rights by German pharmaceutical companies

mso-fareast-font-family:SimSun;mso-ansi-language:EN-US;mso-fareast-language:
ZH-CN;mso-bidi-language:AR-SA">
A research team from Duke-NUS Medical School’s Cardiovascular & Metabolic Disorders Programme, SingHealth Duke-NUS Academic Medical Centre, National Heart Centre Singapore and the Singapore-based biotech company, Enleofen Bio had discovered the role of a specific protein – interleukin 11 (IL-11) – in fibrotic diseases of the liver, lung, kidney, eye, skin and heart.